Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 2
1976 1
1978 2
1979 4
1980 3
1981 2
1982 8
1983 2
1984 3
1985 3
1986 8
1987 8
1988 15
1989 5
1990 8
1991 11
1992 15
1993 19
1994 9
1995 10
1996 14
1997 11
1998 20
1999 15
2000 13
2001 15
2002 18
2003 6
2004 16
2005 26
2006 20
2007 32
2008 26
2009 22
2010 29
2011 23
2012 26
2013 25
2014 38
2015 43
2016 36
2017 47
2018 48
2019 38
2020 51
2021 45
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

765 results
Results by year
Filters applied: . Clear all
Page 1
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. Souers AJ, et al. Among authors: tse c. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6. Nat Med. 2013. PMID: 23291630
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Carey LA, et al. Among authors: tse ck. JAMA. 2006 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492. JAMA. 2006. PMID: 16757721
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH, Tarrant JM, La N, Wang L, Tao ZF, Wendt MD, Sampath D, Rosenberg SH, Tse C, Huang DC, Fairbrother WJ, Elmore SW, Souers AJ. Leverson JD, et al. Among authors: tse c. Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642. Sci Transl Med. 2015. PMID: 25787766
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. Tse C, et al. Cancer Res. 2008 May 1;68(9):3421-8. doi: 10.1158/0008-5472.CAN-07-5836. Cancer Res. 2008. PMID: 18451170 Free article.
Predicting protein druggability.
Hajduk PJ, Huth JR, Tse C. Hajduk PJ, et al. Among authors: tse c. Drug Discov Today. 2005 Dec;10(23-24):1675-82. doi: 10.1016/S1359-6446(05)03624-X. Drug Discov Today. 2005. PMID: 16376828 Review.
[The microRNAs as biomarkers: What prospects?].
Zendjabil M, Favard S, Tse C, Abbou O, Hainque B. Zendjabil M, et al. Among authors: tse c. C R Biol. 2017 Feb;340(2):114-131. doi: 10.1016/j.crvi.2016.12.001. Epub 2017 Jan 9. C R Biol. 2017. PMID: 28081967 Free article. Review. French.
765 results